Crescent Biopharma, Inc. (CBIO)
NASDAQ: CBIO · Real-Time Price · USD
14.91
+0.79 (5.59%)
Oct 9, 2026, 4:00 PM EDT - Market closed
Company Description
Crescent Biopharma, Inc., a biotechnology company, researches and develops cancer therapy candidates in the United States.
Its pipeline includes CR-001, which is in Phase 3 clinical trial, a proprietary anti-PD-1/anti-VEGF bispecific antibody to treat solid tumors; and CR-002, and CR-003.
The company has a strategic partnership with Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. for the development and commercialization of oncology therapeutics.
The company was formerly known as GlycoMimetics, Inc. The company was founded in 2024 and is headquartered in Waltham, Massachusetts.
Crescent Biopharma, Inc.
| Country | United States |
| Founded | 2003 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 69 |
| CEO | Joshua Brumm |
Contact Details
Address: 300 Fifth Avenue Waltham, Massachusetts 02451 United States | |
| Phone | 617 460 5595 |
| Website | crescentbiopharma.com |
Stock Details
| Ticker Symbol | CBIO |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001253689 |
| CUSIP Number | G2545C104 |
| ISIN Number | KYG2545C1042 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Joshua T. Brumm | Chief Executive Officer and Director |
| Dr. Jonathan McNeill M.D. | President and Chief Operating Officer |
| Dr. Ellie Im M.D. | Chief Medical Officer |
| Richard William Scalzo M.B.A. | Chief Financial Officer |
| Ryan Lynch | Senior Vice President of Finance, Treasurer and Chief Accounting Officer |
| Dr. Wenjie Cheng Ph.D. | Senior Vice President of Technical Operations |
| Dr. Jan Pinkas Ph.D. | Chief Scientific Officer |
| Barbara Bispham Hale J.D. | General Counsel and Corporate Secretary |
| Amy Reilly | Chief Communications Officer |
| Christopher Doughty | Chief Business Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Sep 18, 2026 | S-8 | Securities to be offered to employees in employee benefit plans |
| Sep 17, 2026 | 144 | Filing |
| Sep 17, 2026 | 144 | Filing |
| Sep 16, 2026 | 144 | Filing |
| Sep 16, 2026 | 144 | Filing |
| Aug 14, 2026 | SCHEDULE 13G/A | Filing |
| Jul 31, 2026 | EFFECT | Notice of Effectiveness |
| Jul 30, 2026 | POS AM | Post-Effective amendments for registration statement |
| Jul 30, 2026 | 424B3 | Prospectus |
| Jul 30, 2026 | 10-Q | Quarterly Report |